Innova Vascular

Coming – November 17

New Life Saving Treatment For Millions With Blood Clots

Date and Time

November 17

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Venous thromboembolism (VTE) is a life-threatening condition that affects over 1 million people and causes more than 100,000 deaths annually in the U.S.

Innova Vascular is addressing this urgent challenge with FDA-cleared medical devices for VTE designed to remove dangerous blood clots more effectively and safely than existing options.

The VTE device market is projected to nearly double to $2.8 billion by 2030, growing at 12–15% annually. Innova has demonstrated early commercial success with over $2 million in revenue from limited release, strong physician endorsements, and a robust IP portfolio. With attractive reimbursement levels, healthy margins, and proven manufacturability, and a team with significant experience in this space, the company is well-positioned for rapid growth.

Register today to join our Fireside Chat with Innova Vascular CEO, Dr. Sanjay Shrivastava, to hear why their products have already been adopted by over 20 U.S. hospitals, with physicians reporting improved outcomes compared to current market leaders

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.